Cargando…

Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients

Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Matar, Kamal M., Al-lanqawi, Yousef, Abdul-Malek, Kefaya, Jelliffe, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/
https://www.ncbi.nlm.nih.gov/pubmed/23484093
http://dx.doi.org/10.1155/2013/202818
_version_ 1782260378291404800
author Matar, Kamal M.
Al-lanqawi, Yousef
Abdul-Malek, Kefaya
Jelliffe, Roger
author_facet Matar, Kamal M.
Al-lanqawi, Yousef
Abdul-Malek, Kefaya
Jelliffe, Roger
author_sort Matar, Kamal M.
collection PubMed
description Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorithm. The estimations of the developed model were assessed using mean error (ME) as a measure of bias and mean squared error (MSE) as a measure of precision. A total of 331 serum amikacin concentrations were obtained from 56 patients. The mean (±SD) model parameter values found were V (c) = 0.2302 ± 0.0866 L/kg, k (slope) = 0.004045 ± 0.00705 min per unit of creatinine clearance, k (12) = 2.2121 ± 5.506 h(−1), and k (21) = 1.431 ± 2.796 h(−1). The serum concentration data were estimated with little bias (ME = −0.88) and good precision (MSE = 13.08). The present study suggests that amikacin pharmacokinetics in adult Kuwaiti ICU patients are generally rather similar to those found in other patients. This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient.
format Online
Article
Text
id pubmed-3581152
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35811522013-03-12 Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients Matar, Kamal M. Al-lanqawi, Yousef Abdul-Malek, Kefaya Jelliffe, Roger Biomed Res Int Research Article Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorithm. The estimations of the developed model were assessed using mean error (ME) as a measure of bias and mean squared error (MSE) as a measure of precision. A total of 331 serum amikacin concentrations were obtained from 56 patients. The mean (±SD) model parameter values found were V (c) = 0.2302 ± 0.0866 L/kg, k (slope) = 0.004045 ± 0.00705 min per unit of creatinine clearance, k (12) = 2.2121 ± 5.506 h(−1), and k (21) = 1.431 ± 2.796 h(−1). The serum concentration data were estimated with little bias (ME = −0.88) and good precision (MSE = 13.08). The present study suggests that amikacin pharmacokinetics in adult Kuwaiti ICU patients are generally rather similar to those found in other patients. This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient. Hindawi Publishing Corporation 2013 2013-01-30 /pmc/articles/PMC3581152/ /pubmed/23484093 http://dx.doi.org/10.1155/2013/202818 Text en Copyright © 2013 Kamal M. Matar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Matar, Kamal M.
Al-lanqawi, Yousef
Abdul-Malek, Kefaya
Jelliffe, Roger
Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title_full Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title_fullStr Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title_full_unstemmed Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title_short Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
title_sort amikacin population pharmacokinetics in critically ill kuwaiti patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/
https://www.ncbi.nlm.nih.gov/pubmed/23484093
http://dx.doi.org/10.1155/2013/202818
work_keys_str_mv AT matarkamalm amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients
AT allanqawiyousef amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients
AT abdulmalekkefaya amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients
AT jellifferoger amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients